ALK and non-small cell lung carcinoma: Our retrospective study provided first-hand data of the effectiveness and safety of crizotinib treatment, brain metastases, progression patterns and sequential therapy beyond crizotinib in patients with advanced ALK-positive NSCLC in Chinese routine clinical practice at Fudan University Shanghai Cancer Center.